Novavax's revenue has collapsed 91.5% from its 2025Q1 peak of $666.7M to $56.7M in 2026Q2, reflecting the boom-bust nature of COVID vaccine demand. Gross margins remain high at 74.9% in 2026Q2, but operating leverage has swung to a -96.8% operating margin, and...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 6, 2026 | -$0.32+15.8% vs -$0.38 | $57M+8.0% vs $53M |
Q2 2026 May 6, 2026 | -$0.06+76.0% vs -$0.25 | $140M+74.8% vs $80M |
Q1 2026 Feb 26, 2026 | $0.11+116.7% vs -$0.66 | $147M+63.8% vs $90M |
Q4 2025 Nov 6, 2025 | -$1.25-15.7% vs -$1.08 | $70M+67.2% vs $42M |
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Benchmark NVAX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Novavax, Inc. (NVAX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.83 | $1.78B | 4.26 | 64.69% | 39.19% | — | — | |
| $182.56 | $72.44B | -25.15 | -39.23% | -141.43% | -39.2% | — | |
| $100.87 | $25.34B | -19.50 | 0.2% | -64.02% | -9.13% | — | |
| $27.93 | $159.19B | 20.54 | -1.65% | 6.81% | 4.87% | — | |
| $42.51 | $102.08B | 11.58 | 5.49% | 8.09% | 5.5% | — | |
| $50.72 | $101.62B | 13.66 | 4.11% | 14.52% | 24.99% | — |
Novavax, Inc. (NVAX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Novavax, Inc. (NVAX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 23, 2026·SEC
May 6, 2026·SEC
Get notified when NVAX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Novavax, Inc. (NVAX) stock FAQ — growth, dividends, profitability & financials explained
Novavax, Inc. (NVAX) reported $413.8M in revenue for fiscal year 2025. This represents a 413696% increase from $0.1M in 1996.
Novavax, Inc. (NVAX) grew revenue by 64.7% over the past year. This is strong growth.
Novavax, Inc. (NVAX) reported a net loss of $247.7M for fiscal year 2025.
Novavax, Inc. (NVAX) had negative free cash flow of $43.6M in fiscal year 2025, likely due to heavy capital investments.
